Skip to main content
🧬Peptide Protocol Wiki

Humanin: Community Protocols & Reports

Aggregated community experiences, protocols, and stacking patterns

Anecdotal ReportsBased on 25 community reports

Community-Sourced Information

The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.

For peer-reviewed dosing protocols, see the clinical dosing guide.

Browse community protocols for all 130 peptides →

Reviewed byEditorial Team
📅Updated February 16, 2026
Unverified

📌TL;DR

  • 3 community protocols documented
  • Evidence level: Anecdotal Reports
  • Based on 25 community reports
  • 3 stacking patterns reported

Clinical vs. Community Protocol Differences

How community-reported protocols differ from clinical research protocols.

AspectClinical ApproachCommunity ApproachSignificance
Analog SelectionResearch uses both native humanin and the S14G-humanin (HNG) analog, which is approximately 1000-fold more potent. Most published studies use HNG at doses of 0.5-4 mg/kg in mice, administered IP or SubQ.Community predominantly uses HNG (S14G-humanin) due to its greater potency. However, product labeling and vendor specification of which analog is being sold is inconsistent, creating uncertainty about what community members are actually using.high

The 1000-fold potency difference between native humanin and HNG makes proper analog identification critical. Dosing appropriate for HNG could be vastly different from dosing for native humanin.

Evidence BaseNo human clinical trials exist. Research is limited to cell culture, animal models, and observational studies showing correlation between endogenous humanin levels and longevity (centenarian studies).Community use is extrapolated from mouse studies showing metabolic and anti-aging benefits of HNG treatment, and from the observation that centenarians' offspring have higher circulating humanin levels.high

The centenarian association is correlation, not causation. Higher endogenous humanin levels may be a marker of mitochondrial health rather than a cause of longevity. Supplementing exogenous humanin may not recapitulate this association.

DosingMouse studies typically use HNG at 2-4 mg/kg IP twice weekly. For a 70 kg human, allometric scaling suggests approximately 0.3 mg/kg HED, or roughly 21 mg per dose.Community uses 1-5 mg per injection, lower than strict allometric scaling would suggest. This may reflect cost constraints, safety caution, or the finding that the HNG analog is already highly potent.moderate

Community doses are lower than HED-scaled mouse doses but may be appropriate given HNG's high potency. The optimal human dose is entirely unknown.

Compare these community approaches with published research findings.

Community Protocols

Standard HNG Analog Protocol

Common
Route
Subcutaneous
Dose
1-5 mg
Frequency
2-3 times weekly
Duration
4-8 weeks on, 2-4 weeks off

Uses the potent S14G-humanin (HNG) analog at lower doses than native humanin; most community users prefer HNG

Higher-Dose Weekly Protocol

Niche
Route
Subcutaneous
Dose
5-10 mg total per week
Frequency
Divided into 2-3 injections
Duration
2-4 weeks on, 2-4 weeks off

Higher dose approach for more pronounced anti-aging effects; divided across multiple weekly injections

Low-Dose Daily Protocol

Niche
Route
Subcutaneous
Dose
0.5-1 mg
Frequency
Once daily
Duration
4-8 weeks

Daily low-dose approach for sustained mitochondrial support; less common due to injection burden

Stacking Patterns

Humanin + MOTS-c MDP Stack

Niche

Combining two mitochondrial-derived peptides for anti-apoptotic protection (Humanin) and metabolic regulation (MOTS-c)

Humanin + SS-31 Mitochondrial Stack

Niche

Humanin for cytoprotection via STAT3/AKT signaling combined with SS-31 for cardiolipin stabilization and electron transport chain support

Humanin + Epitalon Anti-Aging Stack

Niche

Multi-pathway anti-aging combination targeting mitochondrial protection (Humanin) and telomere maintenance (Epitalon)

Check stack compatibility and review potential side effects before combining peptides.

Unlock community dosing protocols and stacking combos

See the exact doses, routes, and schedules 25+ self-experimenters report. Free with email.

150+ peptide profiles · 30+ comparisons · 18 research tools

Already subscribed?

Sources

Community Evidence Overview#

This page presents aggregated community protocols and anecdotal reports for Humanin. The information below is gathered from peptide research forums, Reddit communities, and self-experimenter reports. This is not clinical evidence and should not be used as medical guidance.

Humanin is one of the three major mitochondrial-derived peptides (along with MOTS-c and SHLP peptides), discovered in 2001 from surviving neurons in Alzheimer's disease brains. Community interest is driven by its anti-apoptotic properties, the centenarian longevity association, and its role as an endogenous cytoprotective factor.

Understanding Protocol Divergence#

Analog Confusion#

A significant practical challenge in the humanin community is the distinction between native humanin and the HNG (S14G-humanin) analog. HNG is approximately 1000-fold more potent, meaning appropriate dosing differs dramatically between the two forms. Vendor labeling is not always clear, creating uncertainty about what users are actually administering.

Endogenous vs. Exogenous#

Humanin is naturally produced by human mitochondria, and endogenous levels correlate with longevity. However, supplementing with exogenous humanin is a fundamentally different intervention than having naturally high endogenous production. The relationship between circulating humanin levels, mitochondrial health, and longevity is complex and may not be recapitulated by external supplementation.

Commonly Reported Outcomes#

Community reports for humanin include:

  • General well-being: Some users report improved overall sense of vitality and well-being
  • Recovery: Reports of improved recovery from physical and metabolic stress
  • Subtle effects: Most users describe effects as subtle and difficult to attribute specifically to humanin
  • Well-tolerated: Generally reported as well-tolerated with minimal side effects
  • Long-term focus: Users tend to frame humanin use as a long-term anti-aging strategy rather than expecting acute effects

Important Caveats#

  • No human clinical trials exist for humanin
  • The centenarian longevity association is correlational, not causal
  • Analog identification (humanin vs. HNG) is critical for proper dosing
  • Chronic anti-apoptotic signaling has theoretical cancer risk implications
  • Effects are difficult to measure without biomarker tracking

Subscribe to see vendor options

Free access to verified vendor scores, pricing, and suppliers.

150+ peptide profiles · 30+ comparisons · 18 research tools

Already subscribed?

Frequently Asked Questions About Humanin

Explore Further

⚠️

Medical Disclaimer

This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.